Promising preclinical data prompted the launch of three phase I/II clinical trials aimed at assessing the safety and efficacy of ROBO-1-directed CAR-NK cell therapy in PDAC and other solid tumors depending on ROBO-1 expression on cancer cells, which are currently enrolling patients in China (NCT03941457, NCT03940820, NCT03931720). The gene discussed is ROBO1; the disease is cancer.